Dr. Min Chiu Li was the first scientist to demonstrate that systemic chemotherapy could cure widely metastatic, malignant cancer. Born in 1919 in Mukden (now Shenyang), China, he studied at Mukden Medical College and moved to the United States in 1947 for further medical training due to the Chinese Civil War. He trained at the University of Southern California, worked as a resident at Chicago’s Presbyterian Hospital, and later joined the National Cancer Institute (NCI) in 1955.
The Trailblazer Who Defied Odds: Dr. Min Chiu Li’s Story
In the bustling city of Mukden, China, in 1919, Min Chiu Li was born into a world of change and uncertainty. The son of a school principal, young Min was a curious boy, always asking questions about the world around him. “Why do people get sick, Baba?” he’d ask his father, peering over books in their modest home. “Some mysteries are for you to solve, Min,” his father would reply with a knowing smile.
By his early 20s, Min was studying medicine at Mukden Medical College, his sharp mind drawn to the puzzle of human health. But the Chinese Civil War tore through his plans. In 1947, with conflict raging, he made the heart-wrenching decision to leave his homeland for the United States. “I’ll come back one day,” he promised his family, clutching a single suitcase as he boarded a ship to a new life.
Landing in California, Min threw himself into medical training at the University of Southern California, then honed his skills as a resident at Chicago’s Presbyterian Hospital. By 1955, he’d earned a coveted spot at the National Cancer Institute (NCI), where his destiny as a cancer pioneer began to unfold.
At NCI, Min focused on choriocarcinoma, a rare and deadly placental cancer that ravaged young women, often killing them within a year. The medical world saw it as a lost cause. But Min wasn’t one to accept defeat. In the lab, surrounded by test tubes and patient charts, he pored over data late into the night. “There’s got to be a way,” he muttered to himself, testing methotrexate, a new chemotherapy drug.
One day, a breakthrough: Min noticed that human chorionic gonadotropin (hCG), a hormone produced by the cancer, could be measured in patients’ urine. It was a clue—a way to track the disease even when tumors weren’t visible. “This is it!” he exclaimed to a skeptical colleague, Dr. Roy Hertz. “If we keep treating until the hCG is gone, we can stop the cancer for good.”
“Min, you’re giving them too much poison,” Hertz warned, echoing the era’s fear of chemotherapy’s toxicity. “The tumors are gone. Why keep going?”
“Because the cancer’s still hiding,” Min insisted, his voice steady but urgent. “We stop now, it comes back. We have to finish the fight.”
His method was radical: continue chemotherapy even after tumors vanished, until hCG levels hit zero. Against the odds, his patients began to recover—women who’d been given months to live were walking out of the hospital, cured. One patient, a young mother named Sarah (a fictional name for narrative), grabbed his hand, tears in her eyes. “Dr. Li, I get to see my daughter grow up because of you.”
But not everyone celebrated. NCI administrators were furious. “You’re experimenting on patients!” one barked during a heated meeting in 1957. “This is reckless!”
“It’s saving lives,” Min shot back, his jaw tight. “The data proves it.” But the higher-ups didn’t budge. That year, Min was fired, his career in tatters. As he packed his office, he whispered to himself, “They’ll see one day.”
And they did. Within years, studies confirmed Min’s approach: patients treated until hCG normalized were cured, while those who stopped early relapsed. His work revolutionized cancer treatment, introducing the concept of tumor biomarkers and adjuvant chemotherapy—using drugs to kill invisible cancer cells post-treatment. By 1960, he’d shown chemotherapy could cure metastatic testicular cancer, and in 1977, he boosted survival rates for colon cancer with fluorouracil.
Min’s persistence earned him the prestigious Lasker-DeBakey Clinical Medical Research Award in 1972. At the ceremony, he stood humbly, thinking of his patients. “This is for them,” he said softly to his wife, who squeezed his hand. In 1975, he returned to his roots, serving as Chairman of the National Cancer Research Committee in Taiwan, a homecoming that felt like a full circle.
Dr. Min Chiu Li passed away in 1980, but his legacy burns bright. Thanks to him, choriocarcinoma is now one of the most curable cancers, often treated without surgery. The boy from Mukden, who once dreamed of solving mysteries, had changed the world.
“Keep asking questions, Min,” his father’s voice echoed in his mind. And he did—until the very end.
At NCI, Li focused on choriocarcinoma, a highly lethal placental cancer. He used methotrexate, an antifolate chemotherapy drug, and made a groundbreaking discovery: monitoring human chorionic gonadotropin (hCG) levels in patients’ urine could measure treatment effectiveness. Li insisted on continuing chemotherapy until hCG levels normalized, even after visible tumors disappeared, a practice that was controversial at the time. This approach led to complete remission in several patients, curing a cancer that previously had a 90% mortality rate within a year. His persistence, however, led to his dismissal from NCI in 1957, as administrators believed he was unnecessarily exposing patients to toxic drugs. Subsequent evidence validated his approach, showing that patients who stopped treatment early relapsed, while those treated until hCG normalized were cured.
Li’s work established key principles in cancer treatment, including the use of tumor biomarkers and adjuvant chemotherapy. He later demonstrated chemotherapy’s effectiveness for metastatic testicular cancer in 1960 and improved colon cancer survival rates with fluorouracil in 1977. For his contributions, he received the Lasker-DeBakey Clinical Medical Research Award in 1972 and served as Chairman of the National Cancer Research Committee of Taiwan’s National Science Council in 1975.
Li’s legacy transformed medical oncology, making choriocarcinoma one of the most curable cancers today, often without surgery. He passed away in 1980.
deemagclinic
deemag and chest clinic 